Thyroid Hormone Study
HairDAO's first funded research study. The study tests whether FDA-approved, topically-applied T3 and T4 promote the production of key growth factors, metabolism, and stem cell activities on human scalp skin to treat androgenic alopecia. Despite being some of the most prescribed drugs in the world, topical T3 and T4 have never been used for any dermatological indication, including hair regrowth.
HairDAO has sent funds to Dr. Paus to begin the study. Dr. Paus will deliver its initial results to HairDAO by May 2023, at which point the DAO will vote on whether or not to test a combination of T3 and T4.
Cyanidin 3-O-arabinoside (C3A), a natural compound found in black chokeberries (aronia melanocarpa), has been shown to protect human dermal papilla (DP) cells against mitochondrial-generated reactive oxygen species (ROS), fully mitigating human DP cellular senescence when exposed to dihydrotestosterone (DHT). C3A's mechanism of action is still unknown, as its stability and long-term safety.
HairDAO is in contact with researchers who have experience working with anthocyanins, to solve for the high cost and unstable nature of C3A.
Stemson Therapeutics is attempting to generate de novo hair follicles from induced pluripotent stem cells (IPSCs). If successful, their approach would allow for limitless donor hairs in hair transplants, which is currently the most significant constraint for the procedure.
Continual due diligence on the company. Stemson's CEO Geoff Hamilton has generously agreed to do a Q&A with the HairDAO community.
TRPM5 Agonist Study
Cutaneon GmbH owns the patents to TRPM5 agonist pheromones indicated for hair regrowth. Ralf Paus, the CEO of Cutaneon, has proposed that we test the effect TRPM5 in combination with one or two other novel hair growth-stimulatory oderants or tastants, to identify and patent hair growth-stimulatory cosmeceuticals.
Study design in process.
Hair Loss Cellular Mapping
A base level sequencing and spatialomics mapping of the relevant cells in the hair loss process would be a highly valuable data for the global hair research community. Based on our initial findings, we would have the ability to patent and pursue the pathways and molecules we are most excited about, before open-sourcing or licensing all of the data to the global hair loss community.
Contact Allergan to analyze benefits of purchasing their pre-existing data. Preliminary information obtained from Dr. Ralf Paus and Dr. Ben Ober-Reynolds.
A medical device company that utilizes hormesis to strengthen hair follicle stem cells in the dermis and epidermis.
A pay-for-success clinical trial to better understand the suitable dosage range of verteporfin injections necessary to reduce or eliminate scarring caused in hair restoration procedures.
Dr. Taleb Bargouthi successfully tested Verteporfin on one hair transplant patient. After promising initial results, our friends at verteporfin.org are now raising funds to support additional patient trials.
The Hairly Adopter
The first $HAIR NFT. Utility known to those who know.
HairDAO rebranding and website design
A total rebranding of HairDAO from the ground up, including a new brand identity and visual communication style, website redesign, and branding for our social properties. The goal was to create a serious but self-aware brand capable of bringing hair loss research into the mainstream.
Identity design complete, and website launched. We worked with our friend Si Maclennan to get the job done.
We are creating a patient database for HairDAO members to upload genomic, treatment protocol, and outcome data, which we can then leverage to 1) provide our members treatment recommendations, 2) place members in clinical trials, and 3) discover new targets for future treatments.
V1 Live with DBDAO as the back-end. V2 scope complete and in development.
Initial Token Auction
The Initial Auction brings the HAIR token to the wild. HAIR will serve as a governance instrument, with 1 HAIR equal to 1 vote. 125k HAIR was sold in the auction at the price of $2.28 per HAIR. The first HAIR holders then voted for a 1.53mn total HAIR supply in HIP-2.
Auction scheduled for February 2023.
The HAIR API enables us to partner with Compounding Pharmacies, to offer our members today’s best treatments. Any profits from the sales of our customized solutions are re-invested into research & development, necessary to create tomorrow’s treatments.
In contact with Compounding Pharmacies and Medical Directors.
In combination with the projects above, there is a sea of ideas still budding in the pre-clinical stage. The best way to accelerate their growth is to join us. We always welcome new people, perspectives, and projects.
Ideas that we have thought were the worst ultimately became our best, and vice-versa. Please submit any project that you believe will help us solve hair loss faster.